US 10485803
Pyrimidine compounds as JAK kinase inhibitors
granted A61KA61K31/519A61P
Quick answer
US patent 10485803 (Pyrimidine compounds as JAK kinase inhibitors) held by Theravance Biopharma R&D IP, LLC expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K31/519, A61P, A61P1/00, A61P1/04